JPRN-jRCT2051200155已完成1 期
DS-6016a Phase I Study- Single ascending dose study to assess the safety, tolerability, and pharmacokinetics of DS-6016a after subcutaneous injection in healthy Japanese subjects.
Inoguchi Akihiro0 个研究点目标入组 48 人开始时间: 2021年3月12日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 45age old（—）
- 性别
- Male
入选标准
- •1. Japanese healthy male subjects.
- •2. Age >=20 and <=45 years upon providing informed consent.
- •3. Body mass index (BMI) >=18.5 and <25.0 kg/m2 at screening.
排除标准
- •1. Having a history of hypersensitivity to any drugs or substances, or being idiosyncratic (eg, having penicillin allergy)
- •2. Having alcohol or drug dependence etc.
研究者
相似试验
已完成
1 期
Study of Single-Ascending Doses of DS-6016a in Healthy Japanese SubjectsFibrodysplasia Ossificans ProgressivaNCT04818398Daiichi Sankyo Co., Ltd.48
已完成
不适用
Investigating a new Vaccine Against Meningitis B (in Oxford)Meningitis BInfections and InfestationsNeisseria meningitidis serotype BISRCTN46336916niversity of Oxford88
已完成
1 期
Study to evaluate the concentrations and safety/tolerability of IV DM199 when administered in a PVC bagAdult healthy participants (Part A) and adults recently taking ACE inhibitors (Part B)ISRCTN54869523DiaMedica Therapuetics, Inc.12
已完成
1 期
Phase I Single- and Multiple-Ascending Dose Trial of EVX-101Mental and Behavioural DisordersDepressionISRCTN42835524Evecxia Therapeutics Inc.38
已完成
不适用
A Phase I Single Arm Dose Escalation Study of the Combination of Dasatinib (Sprycel) with Lenalidomide (Revlimid) and Dexamethasone (Decadron) in Subjects with Relapsed and/or Refractory Multiple Myeloma10027656Multiple MyelomaNL-OMON31724Bristol-Myers Squibb9